^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL2 rearrangement

    i
    Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (NCT03223610)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/09/2018
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6 • CD4
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Onureg (azacitidine oral) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (NCT04833114)
    Phase 3
    GWT-TUD GmbH
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/30/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA) (NCT03570892)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    05/07/2019
    Primary completion :
    05/06/2021
    Completion :
    02/14/2026
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
    Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (NCT06093841)
    Phase 2
    Shanghai Ming Ju Biotechnology Co., Ltd.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    11/03/2023
    Primary completion :
    01/21/2024
    Completion :
    11/04/2029
    BCL2
    |
    MYC rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)
    Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (NCT03742258)
    Phase 1
    Northwestern University
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/13/2019
    Primary completion :
    03/12/2021
    Completion :
    12/19/2028
    MYC • BCL2 • BCL6
    |
    MYC overexpression • MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • mivavotinib (CB-659) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/18/2021
    Primary completion :
    01/02/2024
    Completion :
    06/01/2025
    ALK • MYC • BCL2 • CD8 • TNFRSF8 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Copiktra (duvelisib) • Onureg (azacitidine oral)
    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/09/2021
    Primary completion :
    10/29/2025
    Completion :
    10/29/2030
    BCL2 • BCL6 • UGT1A1
    |
    MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)
    A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (CRC-403) (NCT05169489)
    Phase 1/2
    Regeneron Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/24/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    bbT369
    Study of IMPT-314 in R/R Aggressive B-cell NHL (MPCT-012L) (NCT05826535)
    Phase 1/2
    ImmPACT Bio
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    05/09/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2029
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    rondecabtagene autoleucel (LYL314)
    Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) (NCT05459571)
    Phase 2
    Kite, A Gilead Company
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    08/09/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV